We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest trading session, Amgen (AMGN - Free Report) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. On the other hand, the Dow registered a loss of 0.16%, and the technology-centric Nasdaq increased by 1.63%.
Shares of the world's largest biotech drugmaker have depreciated by 1.29% over the course of the past month, underperforming the Medical sector's loss of 0.32%, and the S&P 500's gain of 8.11%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. In that report, analysts expect Amgen to post earnings of $4.75 per share. This would mark a year-over-year decline of 3.06%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.49 billion, up 4.16% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.18 per share and revenue of $37.81 billion, indicating changes of +1.56% and +2.88%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.66% lower. Amgen is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 15.72 right now. This indicates a discount in contrast to its industry's Forward P/E of 21.28.
It's also important to note that AMGN currently trades at a PEG ratio of 3.64. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 96, positioning it in the top 40% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Amgen (AMGN - Free Report) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. On the other hand, the Dow registered a loss of 0.16%, and the technology-centric Nasdaq increased by 1.63%.
Shares of the world's largest biotech drugmaker have depreciated by 1.29% over the course of the past month, underperforming the Medical sector's loss of 0.32%, and the S&P 500's gain of 8.11%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. In that report, analysts expect Amgen to post earnings of $4.75 per share. This would mark a year-over-year decline of 3.06%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.49 billion, up 4.16% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.18 per share and revenue of $37.81 billion, indicating changes of +1.56% and +2.88%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.66% lower. Amgen is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 15.72 right now. This indicates a discount in contrast to its industry's Forward P/E of 21.28.
It's also important to note that AMGN currently trades at a PEG ratio of 3.64. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.49.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 96, positioning it in the top 40% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.